4th Quarter 2024 Earnings Call January 22, 2025 Cautionary note on Forward-looking statements This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying ...

Key TakeawaysJohnson & Johnson's fourth quarter sales met estimates, while net income fell short.After adjusting for one-time costs like acquisitions, the drug and medical device maker's adjusted profits beat estimates.The company's projections for sales during the 2025 fiscal year also came in short of current analyst estimates. Johnson & Johnson (JNJ) posted its fourth-quarter earnings report Wednesday morning, with adjusted profits beating expectations while the company's sales projections for the coming ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.Pharmaceuticals and medical devices manufacturer Johnson & Johnson (JNJ 0.76%) reported fourth-quarter 2024 results on Wednesday, Jan. 22, that topped analyst consensus estimates. Revenue of $22.5 billion came in just ahead of forecasts for $22.4 billion while adjusted earnings per share (EPS) of $2.04 also surpassed the $1.99 estimate. Although sales surged in the Innovative Medicine ...

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.22 per share when it actually produced earnings of $2.42, delivering a surprise of 9.01%.Over the l ...

Worldwide Sales Performance - Worldwide sales increased by 5.3% to $22,520 million in Q4 2024 compared to $21,395 million in Q4 2023, driven by a 10.0% growth in U.S. sales[1] - Worldwide sales excluding COVID-19 vaccine increased by 5.5% to $22,520 million in Q4 2024 compared to $21,351 million in Q4 2023[2] - Worldwide sales for the twelve months increased by 4.3% to $88,821 million in 2024 compared to $85,159 million in 2023[4] - Worldwide sales excluding COVID-19 vaccine for the twelve months increased by 5.5% to $88,623 million in 2024 compared to $84,042 million in 2023[5] - Sales to customers increased by 4.3% to $88,821 million in 2024 compared to $85,159 million in 2023[13] - Worldwide sales excluding COVID-19 Vaccine grew by 5.5% to $88,623 million, with operational growth of 7.0%[42] U.S. Sales Performance - U.S. sales grew by 10.0% to $13,204 million in Q4 2024, while Europe sales declined by 0.8% to $4,921 million[1] - Innovative Medicine segment sales grew by 4.4% to $14,332 million in Q4 2024, with U.S. sales increasing by 11.1% to $8,977 million[7] - MedTech segment sales increased by 6.7% to $8,188 million in Q4 2024, driven by a 7.6% growth in U.S. sales to $4,227 million[7] - Adjusted operational sales growth for the Innovative Medicine segment was 6.1% worldwide in Q4 2024, with U.S. growth of 11.1%[23] - MedTech segment's adjusted operational sales growth was 7.6% worldwide in Q4 2024, driven by 7.6% growth in both U.S. and international markets[23] - Innovative Medicine segment reported a 4.0% growth worldwide, with U.S. growth at 9.0% and International decline at (2.5)%[25] - MedTech segment showed a 4.8% growth worldwide, with U.S. growth at 6.9% and International growth at 2.6%[25] - Oncology segment sales grew by 19.0% worldwide, driven by a 32.2% increase in U.S. sales[30] - DARZALEX sales increased by 20.9% worldwide, with U.S. sales up 28.9% and International sales up 11.3%[30] - SPRAVATO sales surged by 44.6% worldwide, with U.S. sales up 50.1%[30] - CARVYKTI sales showed significant growth, with U.S. sales at $304 million and International sales at $31 million[30] - Innovative Medicine segment worldwide sales increased by 4.4% to $14,332 million, with US sales growing 11.1% to $8,977 million and international sales declining 5.1% to $5,355 million[31] - Pulmonary Hypertension products worldwide sales grew 7.4% to $1,092 million, driven by 11.6% growth in US sales to $819 million[31] - Xarelto worldwide sales surged 28.5% to $676 million, entirely from US market growth[31] - MedTech segment worldwide sales increased 6.7% to $8,188 million, with US sales up 7.6% to $4,227 million and international sales growing 5.8% to $3,961 million[33] - Cardiovascular products within MedTech segment saw 23.6% worldwide sales growth to $2,062 million, with US sales jumping 25.8% to $1,221 million[32] - Contact Lenses/Other products worldwide sales rose 6.3% to $937 million, with US sales up 6.0% to $396 million[33] - Innovative Medicine segment total worldwide sales increased by 4.0% to $56,964 million in 2024, with US sales growing 9.0% to $33,970 million and international sales declining 2.5% to $22,994 million[38] - US sales of CARVYKTI surged 85.2% to $869 million, contributing to overall Oncology segment growth in the US market[37] - SPRAVATO US sales increased 57.8% to $929 million, driving Neuroscience segment growth in the US market[37] - XARELTO sales remained stable worldwide at $2,373 million, with US sales growing slightly by 0.3%[38] - US MedTech sales grew by 6.9% to $16,332 million, contributing significantly to overall segment performance[40] International Sales Performance - International sales decreased by 0.7% to $9,316 million in Q4 2024, with Western Hemisphere excluding U.S. sales dropping by 2.7% to $1,135 million[1] - Innovative Medicine segment worldwide sales increased by 4.4% to $14,332 million, with US sales growing 11.1% to $8,977 million and international sales declining 5.1% to $5,355 million[31] - MedTech segment worldwide sales increased 6.7% to $8,188 million, with US sales up 7.6% to $4,227 million and international sales growing 5.8% to $3,961 million[33] - Vision products worldwide sales increased 7.9% to $1,303 million, with international sales growing 10.2% to $794 million[33] - Surgical products worldwide sales increased 12.4% to $365 million, driven by 19.3% growth in international sales to $252 million[33] - Innovative Medicine segment total worldwide sales increased by 4.0% to $56,964 million in 2024, with US sales growing 9.0% to $33,970 million and international sales declining 2.5% to $22,994 million[38] - International sales of TREMFYA grew 22.8% to $1,227 million, outperforming the overall Immunology segment's international performance[35] - International MedTech sales increased by 2.6% to $15,525 million, with operational growth of 5.4%[40] Segment Performance - Innovative Medicine segment sales grew by 4.4% to $14,332 million in Q4 2024, with U.S. sales increasing by 11.1% to $8,977 million[7] - MedTech segment sales increased by 6.7% to $8,188 million in Q4 2024, driven by a 7.6% growth in U.S. sales to $4,227 million[7] - Adjusted operational sales growth for the Innovative Medicine segment was 6.1% worldwide in Q4 2024, with U.S. growth of 11.1%[23] - MedTech segment's adjusted operational sales growth was 7.6% worldwide in Q4 2024, driven by 7.6% growth in both U.S. and international markets[23] - Innovative Medicine segment reported a 4.0% growth worldwide, with U.S. growth at 9.0% and International decline at (2.5)%[25] - MedTech segment showed a 4.8% growth worldwide, with U.S. growth at 6.9% and International growth at 2.6%[25] - Immunology segment sales declined by 7.8% worldwide, with U.S. sales down 5.9% and International sales down 11.5%[28] - Oncology segment sales grew by 19.0% worldwide, driven by a 32.2% increase in U.S. sales[30] - DARZALEX sales increased by 20.9% worldwide, with U.S. sales up 28.9% and International sales up 11.3%[30] - SPRAVATO sales surged by 44.6% worldwide, with U.S. sales up 50.1%[30] - CARVYKTI sales showed significant growth, with U.S. sales at $304 million and International sales at $31 million[30] - Adjusted operational sales growth excluding acquisitions, divestitures, and COVID-19 vaccine was 7.6% for Innovative Medicine and 4.7% for MedTech[25] - Innovative Medicine segment worldwide sales increased by 4.4% to $14,332 million, with US sales growing 11.1% to $8,977 million and international sales declining 5.1% to $5,355 million[31] - Pulmonary Hypertension products worldwide sales grew 7.4% to $1,092 million, driven by 11.6% growth in US sales to $819 million[31] - Xarelto worldwide sales surged 28.5% to $676 million, entirely from US market growth[31] - MedTech segment worldwide sales increased 6.7% to $8,188 million, with US sales up 7.6% to $4,227 million and international sales growing 5.8% to $3,961 million[33] - Cardiovascular products within MedTech segment saw 23.6% worldwide sales growth to $2,062 million, with US sales jumping 25.8% to $1,221 million[32] - Vision products worldwide sales increased 7.9% to $1,303 million, with international sales growing 10.2% to $794 million[33] - Contact Lenses/Other products worldwide sales rose 6.3% to $937 million, with US sales up 6.0% to $396 million[33] - Orthopaedics worldwide sales grew 2.1% to $2,315 million, with Hips products increasing 5.2% to $418 million worldwide[32] - Surgical products worldwide sales increased 12.4% to $365 million, driven by 19.3% growth in international sales to $252 million[33] - Abiomed products worldwide sales grew 12.9% to $384 million, with US sales increasing 11.3% to $308 million[32] - Innovative Medicine segment total worldwide sales increased by 4.0% to $56,964 million in 2024, with US sales growing 9.0% to $33,970 million and international sales declining 2.5% to $22,994 million[38] - Oncology segment sales grew 17.7% worldwide to $20,781 million, driven by strong performance of CARVYKTI (92.7% growth to $963 million) and DARZALEX (19.8% growth to $11,670 million)[37] - Immunology segment sales declined 1.2% worldwide to $17,828 million, with TREMFYA showing strong growth of 16.6% to $3,670 million while STELARA declined 4.6% to $10,361 million[35] - Neuroscience segment sales remained flat worldwide at $7,115 million, with SPRAVATO showing significant growth of 56.4% to $1,077 million[37] - Pulmonary Hypertension segment sales increased 12.3% worldwide to $4,282 million, led by OPSUMIT (10.7% growth to $2,184 million) and UPTRAVI (14.9% growth to $1,817 million)[38] - MedTech segment worldwide sales increased by 4.8% to $31,857 million, with operational growth of 6.2%[40] - Cardiovascular segment worldwide sales grew by 21.4% to $7,707 million, driven by strong US growth of 24.2%[39] - Orthopaedics segment worldwide sales rose by 2.4% to $9,158 million, with US sales increasing by 3.0%[39] - Vision segment worldwide sales increased by 1.5% to $5,146 million, with US sales growing by 2.0%[40] - Innovative Medicine worldwide sales grew by 4.4% to $14,332 million, with US sales up 11.1%[41] Financial Performance - Net earnings from Continuing Operations decreased by 17.0% to $3,431 million in Q4 2024 compared to $4,132 million in Q4 2023[11] - Research and development expenses increased by 18.3% to $5,298 million in Q4 2024, representing 23.5% of sales[11] - Gross profit rose by 4.7% to $61,350 million in 2024, with a gross margin of 69.1%[13] - Research and development expense increased by 14.2% to $17,232 million in 2024, representing 19.4% of sales[13] - Net earnings from Continuing Operations grew by 5.6% to $14,066 million in 2024, with a diluted EPS increase of 11.3% to $5.79[13] - Adjusted net earnings from Continuing Operations decreased by 4.6% to $24,242 million in 2024, with a diluted EPS of $9.98[13] - The company incurred $167 million in restructuring costs in 2024 related to the Orthopaedics franchise streamlining[17] - COVID-19 vaccine-related costs totaled $100 million in 2024, primarily for external manufacturing network exit and clinical trial expenses[18] - European Medical Device Regulation (MDR) compliance costs amounted to $204 million in 2024, with implementation substantially completed by Q4 2024[18] COVID-19 Vaccine Impact - Worldwide sales excluding COVID-19 vaccine increased by 5.5% to $22,520 million in Q4 2024 compared to $21,351 million in Q4 2023[2] - Worldwide sales excluding COVID-19 vaccine for the twelve months increased by 5.5% to $88,623 million in 2024 compared to $84,042 million in 2023[5] - COVID-19 vaccine contributed 1.8% to Innovative Medicine's growth, with International impact at 4.2%[25] - COVID-19 vaccine sales plummeted 82.4% worldwide to $198 million in 2024[35] - COVID-19 Vaccine sales declined by 82.4% worldwide to $198 million, reflecting reduced demand[42] Europe Sales Performance - Europe sales excluding COVID-19 Vaccine increased by 3.7% to $20,014 million, driven by operational growth of 4.1%[42]

Earnings Season Overview - The 2024 Q4 earnings season has gained momentum with several consumer staples giants set to report, including Procter & Gamble (PG), Johnson & Johnson (JNJ), and Kimberly-Clark (KMB) [1] Procter & Gamble (PG) - PG shares have declined approximately 3% over the past six months but modestly outperformed the Zacks Consumer Staples sector [3] - Analysts have shown bearish sentiment, with the Zacks Consensus EPS estimate of $1.86 down 2% over recent months, suggesting 1% YoY growth [3] - Forecasted sales of $21.6 billion are 0.7% higher than the year-ago figure [3] - Gross margin expansion has strengthened profitability, and the company reaffirmed its current year guidance [5] - Valuation is in line with historical levels, with a forward 12-month earnings multiple of 22.5X and a PEG ratio of 3.5X [7] - The stock has a Style Score of 'D' for Value [7] Johnson & Johnson (JNJ) - JNJ shares have declined 2% over the past six months but outperformed the Zacks Consumer Staples sector [8] - Analysts have shown slight bearishness, with the Zacks Consensus EPS estimate of $2.00 down modestly, suggesting a 13% YoY decline [8] - Sales are expected to grow 5.3% YoY [8] - Margins have come under pressure, contributing to declining profitability and EPS [10] - Valuation is more attractive than PG, with a forward 12-month earnings multiple of 13.9X and a PEG ratio of 2.4X [12] - The stock has a Style Score of 'B' for Value [13] Kimberly-Clark (KMB) - KMB shares have declined roughly 10% over the past six months, underperforming the Zacks Consumer Staples sector [14] - The EPS outlook remains stable at $1.50 per share, suggesting flat YoY growth [14] - Revenue is expected to decline 3% YoY [14] - Margins have expanded, but this has been largely ignored by investors, with shares remaining flat over a three-year timeframe [16] - Valuation is fair, with a forward 12-month earnings multiple of 16.7X and a PEG ratio of 3.6X [18] - The stock has a Style Score of 'C' for Value [18] Key Themes for Earnings Releases - Margins and top-line growth will be critical factors to watch in the upcoming earnings releases of PG, JNJ, and KMB [20] - Given the defensive nature of these companies, significant post-earnings volatility is unlikely [20]

Johnson & Johnson JNJ will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects $2 in EPS and $22.44 billion in revenues as the company reports before market hours.The stock is down 8.88% over the past year, up 2.79% YTD.Johnson & Johnson's Spravato Wins FDA Nod Ahead Of EarningsJohnson & Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone treatment for adults with major depressive disorder who failed at least two oral antidepressa ...

Group 1 - The article discusses an ongoing investigation related to Johnson & Johnson, focusing on investors who have incurred losses [1] - The law firm Levi & Korsinsky is encouraging affected investors to reach out for assistance regarding the investigation [1] - The investigation may involve potential legal actions against Johnson & Johnson due to the financial losses experienced by investors [1]

Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to Connect ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard treatments does little to nothing to improve depression symptoms in a patient. Previously, Spravato was cleared in the U.S. to use together with an oral antidepress ...